Windsor Regional Cancer Program

Windsor, Canada

Windsor Regional Cancer Program

Windsor, Canada
SEARCH FILTERS
Time filter
Source Type

Dhesy-Thind S.,Juravinski Cancer Center | Dhesy-Thind S.,McMaster University | Fletcher G.G.,McMaster University | Blanchette P.S.,Sunnybrook Odette Cancer Center | And 9 more authors.
Journal of Clinical Oncology | Year: 2017

Purpose: To make recommendations regarding the use of bisphosphonates and other bone-modifying agents as adjuvant therapy for patients with breast cancer. Methods: Cancer Care Ontario and ASCO convened a Working Group and Expert Panel to develop evidencebased recommendations informed by a systematic review of the literature. Results: Adjuvant bisphosphonates were found to reduce bone recurrence and improve survival in postmenopausal patients with nonmetastatic breast cancer. In this guideline, postmenopausal includes patients with natural menopause or that induced by ovarian suppression or ablation. Absolute benefit is greater in patients who are at higher risk of recurrence, and almost all trials were conducted in patients who also received systemic therapy. Most studies evaluated zoledronic acid or clodronate, and data are extremely limited for other bisphosphonates. While denosumab was found to reduce fractures, long-term survival data are still required. Recommendations: It is recommended that, if available, zoledronic acid (4 mg intravenously every 6 months) or clodronate (1,600 mg/d orally) be considered as adjuvant therapy for postmenopausal patients with breast cancer who are deemed candidates for adjuvant systemic therapy. Further research comparing different bone-modifying agents, doses, dosing intervals, and durations is required. Risk factors for osteonecrosis of the jaw and renal impairment should be assessed, and any pending dental or oral health problems should be dealt with prior to starting treatment. Data for adjuvant denosumab look promising but are currently insufficient to make any recommendation. Use of these agents to reduce fragility fractures in patients with low bone mineral density is beyond the scope of the guideline. Recommendations are not meant to restrict such use of bone-modifying agents in these situations. © 2017 by American Society of Clinical Oncology.

Loading Windsor Regional Cancer Program collaborators
Loading Windsor Regional Cancer Program collaborators